Introduction: The therapeutic approach in multiple sclerosis (MS) is radically changing. From the early stages of MS, a hard-hitting approach to treatment is taken with strong anti-inflammatory drugs being a possible therapeutic option. Areas covered: The concept of induction therapy is emerging in the MS therapeutic scenario. Expert opinion: Not all the MS licensed drugs are suitable candidates for induction therapy. The upcoming challenge will be to identify, after a careful and individual assessment of risk/benefit ratio, the ideal patient who is a candidate to such aggressive therapeutic approach.

Induction therapy for the management of early relapsing forms of multiple sclerosis. A critical opinion

D’Amico, Emanuele
Conceptualization
;
2017

Abstract

Introduction: The therapeutic approach in multiple sclerosis (MS) is radically changing. From the early stages of MS, a hard-hitting approach to treatment is taken with strong anti-inflammatory drugs being a possible therapeutic option. Areas covered: The concept of induction therapy is emerging in the MS therapeutic scenario. Expert opinion: Not all the MS licensed drugs are suitable candidates for induction therapy. The upcoming challenge will be to identify, after a careful and individual assessment of risk/benefit ratio, the ideal patient who is a candidate to such aggressive therapeutic approach.
induction therapy; inflammation; Multiple sclerosis; Anti-Inflammatory Agents; Antibodies, Monoclonal; Humans; Immunosuppressive Agents; Induction Chemotherapy; Multiple Sclerosis; Treatment Outcome; Pharmacology; Pharmacology (medical)
File in questo prodotto:
Non ci sono file associati a questo prodotto.

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: http://hdl.handle.net/20.500.11769/360505
Citazioni
  • ???jsp.display-item.citation.pmc??? 2
  • Scopus 6
  • ???jsp.display-item.citation.isi??? 6
social impact